Cargando…

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats

BACKGROUND: Fimasartan (FMS) is a potent angiotensin receptor blocker for the treatment of mild to moderate hypertension. This study aimed to evaluate the transfer of FMS to fetus and breast milk in rats. METHODS: In order to study the transfer to the fetus and nursing pup, pregnant and nursing mate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tae Hwan, Kim, Min Gi, Shin, Soyoung, Chi, Yong-Ha, Paik, Soo-Heui, Lee, Joo-Han, Yoo, Sun Dong, Youn, Yu Seok, Bulitta, Jürgen B., Joo, Sang Hoon, Jeong, Seok Won, Weon, Kwon-Yeon, Shin, Beom Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962410/ https://www.ncbi.nlm.nih.gov/pubmed/27459959 http://dx.doi.org/10.1186/s40360-016-0080-y

Ejemplares similares

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
por: Kim, Song-Yi, et al.
Publicado: (2016)

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved In Situ Absorption Method in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2018)

Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report
por: Park, Dae Hwa, et al.
Publicado: (2017)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2
por: Kim, Soojeong, et al.
Publicado: (2015)

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure
por: Quan, Hailian, et al.
Publicado: (2020)

Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study
por: Cho, Eun Joo, et al.
Publicado: (2019)

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
por: Kim, Tae Hwan, et al.
Publicado: (2017)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study
por: Oh, Gyu Chul, et al.
Publicado: (2020)

Early prophylaxis of cardiomyopathy with beta-blockers and angiotensin receptor blockers in patients with Duchenne muscular dystrophy
por: Lee, Heirim, et al.
Publicado: (2022)

Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
por: Kim, Inho, et al.
Publicado: (2019)

Fimasartan for Remodeling after Myocardial Infarction
por: Lim, Byung-Kwan, et al.
Publicado: (2019)

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
por: Hong, Keun-Sik, et al.
Publicado: (2021)

Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis
por: Kim, Choon OK, et al.
Publicado: (2017)

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial
por: Kang, Min-gu, et al.
Publicado: (2019)

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy
por: Jeon, Eun-Seok, et al.
Publicado: (2022)

A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats
por: Chang, Sung-A, et al.
Publicado: (2015)

Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling
por: Kim, Tae Hwan, et al.
Publicado: (2017)

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
por: Cho, Min Ae, et al.
Publicado: (2020)

Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Patients Following Ablation of Atrial Fibrillation
por: Park, Jeong-Hwan, et al.
Publicado: (2009)

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
por: Kim, Seokuee, et al.
Publicado: (2014)

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study): An Open-Label Observational Study
por: Park, Jeong Bae, et al.
Publicado: (2013)

Severe Hyponatremia Associated with the Use of Angiotensin II Receptor Blocker/thiazide Combinations
por: Kim, Da-Rae, et al.
Publicado: (2013)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
por: Choi, Jin Sun, et al.
Publicado: (2023)

Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis
por: Cho, Jang-Hee, et al.
Publicado: (2018)

Effects of Angiotensin-II Receptor Blocker on Inhibition of Thrombogenicity in a Canine Atrial Fibrillation Model
por: Choi, Jong-Il, et al.
Publicado: (2016)

Weight loss has an additive effect on the proteinuria reduction of angiotensin II receptor blockers in hypertensive patients with chronic kidney disease
por: Ahn, Shin Young, et al.
Publicado: (2018)

Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2018)

Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats
por: Lim, Hyo-Jeong, et al.
Publicado: (2013)

Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea
por: Jung, Mi‐Hyang, et al.
Publicado: (2021)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients
por: Kasahara, Masato, et al.
Publicado: (2009)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

3D-Printed Gastroretentive Sustained Release Drug Delivery System by Applying Design of Experiment Approach
por: Jeong, Hyeon Myeong, et al.
Publicado: (2020)

Physiologically Relevant In Vitro-In Vivo Correlation (IVIVC) Approach for Sildenafil with Site-Dependent Dissolution
por: Kim, Tae Hwan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0h0ihjk87i106ro5vc440uits4